Bluebird up big premarket in response to clinical trial results

|By:, SA News Editor

Shares of bluebird bio (BLUE) are up a whopping 70% premarket on light volume in response to its report of positive initial results for its gene therapy candidate LentiGlobin BB305 as a treatment for beta-thalassemia major. One patient in the LG001 clinical trial and two patients in the HGB-205 study showed significant increases in total hemoglobin and were able to be weaned off blood transfusions. The company expects to report additional results by year end.

There is only one potentially curative therapy for beta-thalassemia patients, allogenic hematopoietic stem cell transplant, but it carries a significant risk of morbidity and mortality.